<DOC>
	<DOCNO>NCT00654381</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability Linagliptin ( BI 1356 ) ( 5 mg 10 mg / daily ) compare placebo give 12 week voglibose 26 week mono therapy patient type 2 diabetes mellitus insufficient glycaemic control . Furthermore , long-term safety evaluate extension treatment 52 week .</brief_summary>
	<brief_title>Japanese P III v Voglibose Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Inclusion criterion : 1 . Japanese patient diagnosis type 2 diabetes mellitus . Antidiabetic therapy stable least 10 week Visit 1 . 2 . Glycosylated haemoglobin A1 ( HbA1c ) 7.0 10.0 % Visit 3 ( begin 2week placebo runin phase ) 3 . Age : &gt; = 20 &lt; = 80 4 . Body Mass Index ( BMI ) &lt; = 40 kg/m2 Exclusion criterion : 1 . Myocardial infarction , stroke transient ischemic attack ( TIA ) within 6 month Visit 1 2 . Impaired hepatic function 3 . History severe allergy/hypersensitivity 4 . Treatment antidiabetic , anti obesity drug , etc 3 month Visit 1 5 . Fasting blood glucose &gt; 240 mg/dl ( =13.3 mmol/L ) Visits 2 3</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>